title: Testosterone Therapy and Prostate Cancer.
abstract: Changes in understanding regarding the relationship of androgens and prostate cancer have led to changes in the use of testosterone therapy. The evidence supports a finite ability of androgens to stimulate prostate cancer growth, with a maximum achieved at low testosterone concentrations, called the saturation model. The saturation point corresponds with maximal androgenic stimulation at 250 ng/dL. Evidence is reviewed herein regarding the relationship of testosterone to prostate cancer and the relatively new practice of offering testosterone therapy to men with a history of prostate cancer. Although no prospective controlled trials have been performed, results have been reassuring.
authors.affiliation: Men's Health Boston, Department of Surgery (Urology), Harvard Medical School, 200 Boylston Street, Suite A309, Chestnut Hill, MA 02467, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Davidson
authors.affiliation: Men's Health Boston, Department of Surgery (Urology), Harvard Medical School, 200 Boylston Street, Suite A309, Chestnut Hill, MA 02467, USA. Electronic address: dr.morgentaler@menshealthboston.com.
authors.forename: Abraham
authors.initials: A
authors.lastname: Morgentaler
mesh_terms: D006801:Humans; D007610:Kallikreins / Q000097:blood / Q000502:physiology; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood / Q000502:physiology; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D013739:Testosterone / Q000097:blood / Q000502:physiology* / Q000627:therapeutic use*
chemical_list: D013739:Testosterone; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
keywords: Androgens; Hypogonadism; Prostate; Prostate cancer; Prostate-specific antigen; Testosterone; Testosterone deficiency